Jang Jang, | |
108 Ferrara Ave, Hazleton, PA 18201-7554 | |
(570) 459-5502 | |
(570) 459-5502 |
Full Name | Jang Jang |
---|---|
Gender | Male |
Speciality | Otolaryngology |
Location | 108 Ferrara Ave, Hazleton, Pennsylvania |
Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1124431952 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207Y00000X | Otolaryngology | MD036521L (Pennsylvania) | Primary |
Mailing Address | Practice Location Address |
---|---|
Jang Jang, 108 Ferrara Ave, Hazleton, PA 18201-7554 Ph: () - | Jang Jang, 108 Ferrara Ave, Hazleton, PA 18201-7554 Ph: (570) 459-5502 |
News Archive
Researchers from A*STAR Institute of Microelectronics (IME) have developed a lateral silicon-based drug screening tool that has demonstrated simultaneous capture of 12 individual cells – 12 times higher throughput than conventional patch clamping. The device can be scaled up to allow 1536 cell-recordings simultaneously, permitting 16 times higher throughput than existing planar patch clamp approach.
Adding once-daily lixisenatide to basal insulin treatment is effective at improving glycemic control in Asian patients with Type 2 diabetes, show study findings.
Scientists at the University of California at Berkeley have devised a method by which they can hear thoughts. They conducted a small study in which they could predict what people were thinking based on their brain activity.
The U.S. Food and Drug Administration today allowed marketing of ClearLLab Reagents (T1, T2, B1, B2, M), the first agency authorized test for use with flow cytometry to aid in the detection of several leukemias and lymphomas, including chronic leukemia, acute leukemia, non-Hodgkin lymphoma, myeloma, myelodysplastic syndrome (MDS) and myeloproliferative neoplasms (MPN).
Cell Therapeutics, Inc. (CTI) today announced the presentation of findings from a preclinical study of PIXUVRI® (pixantrone) that suggest its mechanism of inducing tumor cell death is novel and distinct from that of anthracyclines such as doxorubicin.
› Verified 1 days ago
George J Racho, MD Otolaryngology Medicare: Not Enrolled in Medicare Practice Location: 154 N Church St, Hazleton, PA 18201 Phone: 570-454-7188 |